Novavax's (NVAX) vaccine for respiratory syncytial virus (RSV), which causes respiratory tract...


Novavax's (NVAX) vaccine for respiratory syncytial virus (RSV), which causes respiratory tract infections, produced encouraging results in preclinical studies, inducing anti-RSV antibodies in vitro and cutting infectious RSV in a cotton rat challenge model. In clinical and preclinical studies, antibodies were generated at concentrations "significantly above that found to be protective in both humans and cottons rats." The vaccine is in Phase I and Phase II trials. (PR)

From other sites
Comments (1)
  • Bullnanke
    , contributor
    Comments (6) | Send Message
     
    Very Encouraging!!!!!
    18 Mar 2013, 11:59 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs